{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:33:18Z","timestamp":1794025998276,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.radonc.2026.111642","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:23:57Z","timestamp":1783124637000},"page":"111642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4813-6295","authenticated-orcid":false,"given":"T.","family":"Willigenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-7874","authenticated-orcid":false,"given":"C.","family":"Draulans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-4149","authenticated-orcid":false,"given":"F.J.","family":"Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4089-7399","authenticated-orcid":false,"given":"T.M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-2067","authenticated-orcid":false,"given":"I.","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-6618","authenticated-orcid":false,"given":"A.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-3349","authenticated-orcid":false,"given":"A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-3673","authenticated-orcid":false,"given":"B.A.","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-8005","authenticated-orcid":false,"given":"S.K.B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0107-864X","authenticated-orcid":false,"given":"T.","family":"Pommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8836","authenticated-orcid":false,"given":"B.R.","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.N.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111642_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2026.111642_b0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0015","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2013.394","article-title":"Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up","volume":"109","author":"Creak","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2026.111642_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0030","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of Standard vs Dose-Escalated Radiation Therapy for patients with Intermediate-Risk Prostate Cancer: the NRG Oncology RTOG 0126 Randomized Clinical Trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0060","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0070","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110535","article-title":"Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial","volume":"201","author":"Menne Guricova","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0080","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: 10-year outcomes of the FLAME trial","volume":"43","author":"Menne Guricova","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111642_b0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME Trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.06.033","article-title":"Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"162","author":"Groen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0120","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.clon.2024.08.011","article-title":"Long-term results of hypofractionated radiotherapy with intra-prostatic boosts in men with intermediate- and high-risk prostate cancer: a phase II trial","volume":"36","author":"Chatterjee","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111642_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00345-024-04876-8","article-title":"Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial \u201cGIVE ME FIVE\u201d","volume":"42","author":"Marvaso","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111642_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110883","article-title":"Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)","volume":"208","author":"Spohn","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0155","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.21873\/anticanres.14672","article-title":"Simultaneous Integrated radiotherapy boost to the dominant intraprostatic lesion: final results of a phase I\/II trial","volume":"40","author":"Buwenge","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2026.111642_b0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2009.08.033","article-title":"Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review","volume":"93","author":"Pieters","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. results from the Prostate Cancer results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111642_b0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2010.02.196","article-title":"Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT","volume":"9","author":"Deutsch","year":"2010","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111642_b0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.brachy.2015.09.004","article-title":"Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer","volume":"14","author":"Xiang","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111642_b0180","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.06.020","article-title":"Brachytherapy boost utilization and survival in unfavorable-risk prostate cancer","volume":"72","author":"Johnson","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijrobp.2014.11.018","article-title":"Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis","volume":"91","author":"Smith","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brachy.2022.08.015","article-title":"Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: a prospective phase II trial","volume":"22","author":"Sanmamed","year":"2023","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111642_b0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2016.02.004","article-title":"Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial","volume":"119","author":"Gomez-Iturriaga","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brachy.2013.10.011","article-title":"Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study","volume":"13","author":"Mason","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111642_b0205","first-page":"22","article-title":"PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13014-022-02173-5","article-title":"Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial","volume":"17","author":"Belliveau","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-023-02375-5","article-title":"Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation","volume":"18","author":"Zhong","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijrobp.2009.07.1689","article-title":"Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study","volume":"78","author":"Miralbell","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12032-020-01397-3","article-title":"Phase II prospective trial \u201cgive me five\u201d short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)","volume":"37","author":"Marvaso","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0235","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111642_b0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","article-title":"Magnetic resonance imaging\u2013guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Poon","year":"2023","journal-title":"European Urology Oncology"},{"key":"10.1016\/j.radonc.2026.111642_b0245","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2023.07.044","article-title":"Risk modeling for individualization of the FLAME focal boost approach in external beam radiation therapy for patients with localized prostate cancer","volume":"118","author":"Menne Guricova","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2022.06.020","article-title":"Who needs a mean dose if you can FLAME?","volume":"174","author":"Guricova","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0255","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.annonc.2025.01.017","article-title":"Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG\/RTOG 0126 and SAKK 09\/10 trials","volume":"36","author":"Dal Pra","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac","volume":"151","author":"de Muinck Keizer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0265","doi-asserted-by":"crossref","unstructured":"Muinck Keizer DMd, Willigenburg T, der Voort van Zyp JRNv, Raaymakers BW, Lagendijk JJW, Boer JCJd. Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac. Radiother Oncol. 2021;162:162\u2013169.","DOI":"10.1016\/j.radonc.2021.07.014"},{"key":"10.1016\/j.radonc.2026.111642_b0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging - reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0275","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jmri.26933","article-title":"Histopathological features of MRI-invisible regions of prostate cancer lesions","volume":"51","author":"van Houdt","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2026.111642_b0280","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0285","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2026.111642_b0290","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.ijrobp.2004.07.711","article-title":"Magnetic resonance assessment of prostate localization variability in intensity-modulated radiotherapy for prostate cancer","volume":"60","author":"Villeirs","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brachy.2018.08.006","article-title":"Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy","volume":"18","author":"Shaaer","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111642_b0300","doi-asserted-by":"crossref","unstructured":"Do D, Conlin C, Baxter M, Christodouleas J, Dess R, Dragojevic I, et al. PrecisionPro Fusion: Clinical Validation of an Automated MRI-CT Fusion System for Prostate Radiotherapy Planning. 2025.","DOI":"10.1101\/2025.07.17.25331682"},{"key":"10.1016\/j.radonc.2026.111642_b0305","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijrobp.2025.03.024","article-title":"Multidisciplinary consensus prostate contours on magnetic resonance imaging: educational atlas and reference standard for artificial intelligence benchmarking","volume":"123","author":"Song","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0315","doi-asserted-by":"crossref","unstructured":"Nguyen L, Song Y, Dornisch A, Baxter M, Barrett T, Dale AM, et al. PURE-MRI: An International Study Assessing Physician Accuracy in Delineating the Prostate and Urethra on Prostate MRI. 2025.","DOI":"10.1101\/2025.04.23.25326296"},{"key":"10.1016\/j.radonc.2026.111642_b0320","article-title":"Feasibility and time gain of implementing artificial intelligence-based delineation tools in daily magnetic resonance image-guided adaptive prostate cancer radiotherapy","volume":"33","author":"Konrad","year":"2025","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0325","doi-asserted-by":"crossref","unstructured":"Song Y, Nguyen L, Dornisch A, Baxter M, Barrett T, Dale AM, et al. Urethra contours on MRI: multidisciplinary consensus educational atlas and reference standard for artificial intelligence benchmarking. 2025.","DOI":"10.1101\/2025.07.01.25330656"},{"key":"10.1016\/j.radonc.2026.111642_b0330","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","volume":"117","author":"Lui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0335","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ijrobp.2024.06.007","article-title":"Clinical impact of contouring variability for prostate cancer tumor boost","volume":"120","author":"Zhong","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0340","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-015-3257-5","article-title":"MRI versus (6)(8)Ga-PSMA PET\/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer","volume":"43","author":"Zamboglou","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2026.111642_b0345","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","article-title":"Intraindividual comparison between (68)Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients","volume":"47","author":"Spohn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2026.111642_b0350","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.juro.2016.07.084","article-title":"Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology","volume":"197","author":"Priester","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111642_b0355","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00259-020-05059-4","article-title":"Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer","volume":"48","author":"Draulans","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2026.111642_b0360","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[(68)Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600690","article-title":"Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference","volume":"10","author":"Spohn","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0370","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.prro.2023.08.017","article-title":"Monitoring intrafraction motion of the prostate during radiation therapy: suggested practice points from a focused review","volume":"14","author":"Shimomura","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0375","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652678","article-title":"Influence of urethra sparing on tumor control probability and normal tissue complication probability in focal dose escalated hypofractionated radiotherapy: a planning study based on histopathology reference","volume":"11","author":"Spohn","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0385","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2009.03.007","article-title":"Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging","volume":"75","author":"Adamson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0390","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0395","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00066-007-1695-0","article-title":"Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice","volume":"183","author":"Guckenberger","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2026.111642_b0400","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijrobp.2014.10.049","article-title":"Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy","volume":"91","author":"Lovelock","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0405","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fonc.2020.00539","article-title":"Clinical assessment of prostate displacement and planning target volume margins for stereotactic body radiotherapy of prostate cancer","volume":"10","author":"Levin-Epstein","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2025.104998","article-title":"Kilovoltage triggered imaging for moderately hypofractionated prostate radiotherapy: Insights into intrafraction motion and intervention through log file analysis","volume":"134","author":"Wilkinson","year":"2025","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2026.111642_b0415","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210800","article-title":"MR-guided radiotherapy for prostate cancer: state of the art and future perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2026.111642_b0420","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2017.10.020","article-title":"Magnetic resonance imaging-guided adaptive radiation therapy: a \u201cgame changer\u201d for prostate treatment?","volume":"100","author":"Pathmanathan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0425","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.03.014","article-title":"Real-time image guided ablative prostate cancer radiation therapy: results from the TROG 15.01 SPARK trial","volume":"107","author":"Keall","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111642_b0435","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/acm2.12822","article-title":"Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments","volume":"21","author":"Korpics","year":"2020","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2026.111642_b0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/153303460300200104","article-title":"CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility","volume":"2","author":"King","year":"2003","journal-title":"Technol Cancer Res Treat"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:50:55Z","timestamp":1783147855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":88,"alternative-id":["S0167814026004810"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111642","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111642"}}